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Abstract
Gastrointestinal mucormycosis is an uncommon, invasive, opportunistic fungal infection with a high mortality rate, seen
more commonly in immunocompromised patients. This lethal infection has a wide range of presentations, from coloniza-
tion of peptic ulcers to infiltrative disease and eventually vascular invasion. Here we present a case of upper gastrointestinal
bleeding in an immunocompromised patient, which was proved to be secondary to gastric involvement by mucormycosis.
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Introduction
Gastrointestinal mucormycosis is an uncommon and invasive,
opportunistic fungal infection with a high mortality rate,
seen more commonly in immunocompromised patients [1].
All portions of the gastrointestinal tract can become involved,
with the stomach being the most common site [2]. This
lethal infection has a wide range of presentations, from coloni-
zation of peptic ulcers to infiltrative disease and eventu-
ally vascular invasion. Here we present a case of upper
gastrointestinal bleeding in an immunocompromised patient
which was proved to be secondary to gastric involvement by
mucormycosis.
Case presentation
A 65-year-old male with type 2 diabetes, interstitial lung dis-
ease and rheumatoid arthritis—the latter being treated with
chronic prednisone therapy and leflunomide—presented with
periumblical abdominal pain and dark, tarry stool for the previ-
ous 24 hours. Laboratory testing demonstrated a drop in hemo-
globin from 13.0 to 6.7 g/dL.
A large mass was found on contrast-enhanced computed to-
mography (CT), extending from the esophago-gastric junction
to the mid-gastric body and containing extensive infiltrative
gas (Figure 1). Esophago-gastroduodenoscopy revealed a large,
infiltrative mass with infiltration into the surrounding gastric
mucosa, characterized by dusky, necrotic and ulcerative mu-
cosa with multiple clots (Figure 2). Biopsies were taken and
revealed broad, ribbon-like fungal elements infiltrating the
gastric parenchyma, compatible with mucormycosis (Figure 3).
Lactophenol cotton blue adhesive tape preparation from colony,
showed sporangiophores directly over the sporangium, compat-
ible with rhizopus (Figure 4).
The patient proceeded to surgery for sub-total gastrectomy
with Roux-en-Y esophagojejunostomy.
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Gastrointestinal mucormycosis is an uncommon and invasive
opportunistic fungal infection with a high mortality rate,
seen more commonly in immunocompromised patients [1].
Some of the common risk factors for this infection include
diabetes, inherited immunodeficiencies, immunosuppressants,
solid organ- and hematopoietic stem cell transplant, malnu-
trition, and hematological malignancies, such as lymphoma
and leukemia [2]. A meta-analysis of 929 cases revealed that
the site of infection varies according to the underlying pre-
disposing factor, with the paranasal sinuses being the most
common site (39%, compared with 7% in the gastrointestinal
tract) [3]. All portions of the gastrointestinal tract can
become involved, with the stomach being the most common
site [4].
This lethal infection has a wide range of presentations, from
colonization of peptic ulcers to infiltrative disease and eventu-
ally vascular invasion. Invasion of the vessels by this fungus
causes thrombosis, infraction and tissue necrosis, which can
present as gastrointestinal bleeding [1, 4]. The mortality rate
from gastrointestinal mucor infection is up to 85%,
which makes early diagnosis crucial [3]. Patients should be diag-
nosed based on their histological findings, since the culture is
positive in only 30% of surgical specimens [5]. Treatment is a
combination of early surgical debridement of infected tissue,
along with systemic antifungal therapy (usually parenteral am-
photericin B at 1 mg/kg/day or oral posaconazole at 400 mg,
given twice daily) [1, 6, 7]. Early intervention with a combined
approach will give the patient a better chance of survival, up to
70% [3].
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